Geode Capital Management’s Artelo Biosciences ARTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,799
Closed -$13.9K 4521
2025
Q4
$13.9K Buy
+3,799
New +$29.5K ﹤0.01% 4413
2025
Q3
Sell
-5,344
Closed -$213K 4482
2025
Q2
$213K Buy
5,344
+3,857
+259% +$71.3K ﹤0.01% 3852
2025
Q1
$23.4K Buy
1,487
+523
+54% +$10.5K ﹤0.01% 4320
2024
Q4
$18.4K Hold
964
﹤0.01% 4394
2024
Q3
$19.8K Sell
964
-136
-12% -$3.11K ﹤0.01% 4395
2024
Q2
$27.7K Hold
1,100
﹤0.01% 4399
2024
Q1
$29.7K Hold
1,100
﹤0.01% 4413
2023
Q4
$27.5K Hold
1,100
﹤0.01% 4462
2023
Q3
$28.9K Buy
1,100
+338
+44% +$11.3K ﹤0.01% 4547
2023
Q2
$27.6K Hold
762
﹤0.01% 4613
2023
Q1
$31.8K Hold
762
﹤0.01% 4616
2022
Q4
$39K Buy
762
+69
+10% +$3.6K ﹤0.01% 4658
2022
Q3
$43K Hold
693
﹤0.01% 4796
2022
Q2
$59K Buy
693
+71
+11% +$6.98K ﹤0.01% 4738
2022
Q1
$75K Buy
622
+19
+3% +$2.18K ﹤0.01% 4730
2021
Q4
$84K Hold
603
﹤0.01% 4769
2021
Q3
$128K Buy
603
+82
+16% +$20.8K ﹤0.01% 4601
2021
Q2
$167K Sell
521
-2
-0.4% -$684 ﹤0.01% 4402
2021
Q1
$230K Buy
523
+298
+132% +$127K ﹤0.01% 4070
2020
Q4
$44K Buy
+225
New +$38.7K ﹤0.01% 4188

Other funds holding ARTL

Geode Capital Management's ARTL Position: Q1 2026 in Review

Geode Capital Management sold out of Artelo Biosciences (ARTL) in Q1 2026, closing a stake of 3,799 shares — an estimated $13.9K sold.

Geode Capital Management first reported a position in ARTL in Q4 2020 and held it in 20 quarters. The position peaked at $230K in Q1 2021. 11 funds tracked by Wall St. Rank hold ARTL as of Q1 2026.

  • Geode Capital Management reported no remaining Artelo Biosciences position as of Q1 2026 after selling out during the quarter.
  • Geode Capital Management sold 3,799 Artelo Biosciences shares in Q1 2026, an estimated $13.9K.
  • Geode Capital Management first reported a position in Artelo Biosciences in Q4 2020 and held it in 20 quarters.
  • Geode Capital Management's Artelo Biosciences position peaked at $230K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Artelo Biosciences as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.